{"id":6558,"date":"2025-04-23T12:28:38","date_gmt":"2025-04-23T09:28:38","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6558"},"modified":"2025-04-23T12:28:38","modified_gmt":"2025-04-23T09:28:38","slug":"early-promise-for-new-drug-in-aortic-stenosis-treatment","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/early-promise-for-new-drug-in-aortic-stenosis-treatment\/","title":{"rendered":"Early Promise for New Drug in Aortic Stenosis Treatment"},"content":{"rendered":"<div>Early Promise for New Drug in Aortic Stenosis Treatment<\/div>\n<div>Source:<\/div>\n<div>Highlighted by AHA : March 24, 2025<\/div>\n<div>Original publication: Circulation<\/div>\n<div><\/div>\n<div><\/div>\n<div>1. Objective:<\/div>\n<div><span> \u2022 Investigate the potential of a new drug, ataciguat, to treat aortic stenosis (AS) without TAVR or SAVR.<\/span><\/div>\n<div><\/div>\n<div>2. Mechanism:<\/div>\n<div><span> \u2022 Ataciguat reactivates oxidized soluble guanylate cyclase, reducing signals that drive fibrocalcific aortic valve stenosis (FCAVS).<\/span><\/div>\n<div><\/div>\n<div>3. Study Summary:<\/div>\n<div><span> \u2022 Phase I trial: Ataciguat was well tolerated in patients with FCAVS.<\/span><\/div>\n<div><span> \u2022 Phase II trial: Six months of treatment reduced aortic valve calcification progression by ~70% compared to placebo.<\/span><\/div>\n<div><\/div>\n<div>4. Clinical Significance:<\/div>\n<div><span> \u2022 The drug showed potential to delay or avoid valve replacement procedures in moderate AS cases.<\/span><\/div>\n<div><span> \u2022 Also showed signs of slowing valvular and ventricular dysfunction.<\/span><\/div>\n<div><\/div>\n<div>5. Next Steps:<\/div>\n<div><span> \u2022 A phase III trial is in progress to evaluate long-term efficacy and safety.<\/span><\/div>\n<div><span> \u2022 Further studies are needed to assess broader cardiovascular outcomes.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.123.066523\">https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.123.066523<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early Promise for New Drug in Aortic Stenosis Treatment Source: Highlighted by AHA : March 24, 2025 Original publication: Circulation 1. Objective: \u2022 Investigate the potential of a new drug, ataciguat, to treat aortic stenosis (AS) without TAVR or SAVR. 2. Mechanism: \u2022 Ataciguat reactivates oxidized soluble guanylate cyclase, reducing signals that drive fibrocalcific aortic [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6558","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6558"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6558\/revisions"}],"predecessor-version":[{"id":6562,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6558\/revisions\/6562"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}